Pulmonary hypertension life expectancy and prognosis
Fact-checked by Pulmonary hypertension (PH) life expectancy can vary widely depending on disease type, how severe PH is, and how quickly it is diagnosed and treated. While PH can be a serious and progressive disease, advances in diagnosis, treatment, and ongoing monitoring have improved the outlook for many people living with the condition.
PH occurs when blood pressure in the blood vessels that carry blood from the heart to the lungs is abnormally high. The increased pressure can make the right side of the heart work harder to pump blood through the lungs and, over time, may affect its function.
Because PH includes several different disease types, there is no single survival rate or life expectancy estimate that applies to everyone. The healthcare team can consider factors such as PH type, symptoms, physical function, heart and lung function, and response to treatment to estimate the likely PH prognosis.
Life expectancy with pulmonary hypertension
There is no single answer to how long a person can live with PH. Survival rates vary substantially by PH type and severity, and outcomes have changed as diagnosis and treatment have advanced.
Prognosis of pulmonary arterial hypertension
PH can be classified into five types, or groups, as defined by the World Health Organization (WHO). PH group 1 includes pulmonary arterial hypertension (PAH), which occurs when changes in the small arteries in the lungs make it harder for blood to flow through them.
In a 2024 systematic review, researchers estimated that 61% of adults with PAH included in European studies were alive five years after diagnosis or enrollment in those studies. While fewer studies from North America were included, which prevented researchers from making longer-term estimates, 88% of adults included in those studies were alive after one year. Survival rates were generally lower for people with more severe disease.
Importantly, PAH outcomes have markedly improved in more recent eras, in part due to advances in diagnosis and treatment of PH.
Prognosis of PH due to left heart disease
This type of PH is the most common form and develops when conditions affecting the left side of the heart increase pressure in the blood vessels connecting the lungs to the heart. Its outlook depends in part on the underlying heart condition and how well it can be managed.
A Japanese study published in 2020 reported that about 69% of participants with group 2 PH were alive and transplant-free five years after diagnosis, while five-year survival rates in a 2022 Chinese study were about 65%.
Prognosis of PH due to lung disease or low oxygen levels
Group 3 PH is associated with lung diseases such as chronic obstructive pulmonary disease (COPD) or other conditions that result in low oxygen levels in the body.
In the same Japanese study, about 64% of participants with group 3 PH were alive and had not received a heart or lung transplant five years after diagnosis. But a study in Germany has estimated a five-year survival rate of about 38% among people with this disease type, likely due to differences in the patients studied, disease severity, and treatment.
Prognosis of chronic thromboembolic pulmonary hypertension
Group 4 PH is also called chronic thromboembolic pulmonary hypertension (CTEPH), and refers to PH due to blood clots that become stuck in the lung’s arteries and block blood flow. Unlike PAH, which is generally managed as a chronic progressive disease, CTEPH can potentially be cured in eligible people by removing the blood clots blocking the pulmonary arteries.
The prognosis of Group 4 PH can therefore differ considerably from that of PAH. A 2023 U.K. study found that five-year survival was about 83% among patients who underwent surgery, compared with 49% among those who did not.
However, not everyone with CTEPH can undergo surgery to remove the blood clots. The location of the blockages, overall health, and other factors help determine whether surgery is appropriate. The care team may recommend other treatment options if a patient is not eligible for surgery.
Prognosis of PH with multiple or unclear causes
Group 5 includes PH associated with a variety of conditions that do not fit neatly into the other groups. Because these conditions differ considerably, there is no single survival estimate that applies to everyone in this category.
The Japanese study reported that about 55% of participants with group 5 PH were alive and transplant-free five years after diagnosis. However, the group was small, and the result should be interpreted with caution.
Why early diagnosis and treatment matter
Early diagnosis can offer an opportunity to start appropriate treatment before PH causes more strain on the heart. Current guidelines recommend raising early suspicion for PH and using fast-track referral to specialized PH centers when PAH, CTEPH, or severe PH is suspected.
For PAH, treatment decisions increasingly incorporate individual risk status along with symptoms and other measures of disease severity. The healthcare team may regularly assess symptoms, level of physical activity, walking ability, blood tests, heart function, and other measures to determine a patient’s risk level.
Treatment can also change over time. If risk remains high, the healthcare team may adjust the treatment plan based on response and other findings.
Importantly, life expectancy with PH cannot be estimated from the diagnosis alone. Two people with the same PH group may have very different outcomes because of differences in disease severity, other health conditions, response to treatment, and additional individual factors.
Prognostic factors
A person’s PH prognosis depends on several factors. Because PH includes different diseases, doctors consider a combination of findings rather than relying on one measurement.
Scroll horizontally to view all columns -->
| Clinical variable | Lower risk/positive indicators | Higher risk/poorer prognosis |
|---|---|---|
| Functional class | WHO functional class I or II (minimal or mild physical limitation) | WHO functional class III or IV (marked limitation or symptoms at rest) |
| Exercise capacity | Preserved or higher distance on 6-minute walk test | Markedly reduced or declining 6-minute walk distance |
| Heart strain biomarkers | Normal or low blood levels of brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) |
Significantly elevated or steadily rising BNP and NT-proBNP levels |
| Right heart function | Normal right ventricular size and preserved pumping function | Signs of right-sided heart strain, enlargement, or right heart failure |
| Hemodynamics | Lower pulmonary vascular resistance; preserved cardiac output | Severely elevated pressures and low cardiac output |
| Symptom progression | Stable symptoms over time without syncope (fainting) | Rapidly worsening symptoms or recurrent fainting episodes |
Factors that can influence a person’s outlook include:
- Type of PH: The five PH groups have different causes, treatment options, and outcomes.
- Functional class: This describes how much PH symptoms limit everyday physical activity.
- Exercise capacity: Tests such as the six-minute walk test can help show how well a person tolerates physical activity.
- Heart function: Signs of strain or weakening of the right side of the heart can indicate a higher risk.
- Blood biomarkers: Levels of substances released in response to heart strain, such as BNP and NT-proBNP, can provide information about heart function.
- Hemodynamic measurements: Right heart catheterization is a procedure that directly measures pressures in the heart and pulmonary arteries. These measurements can provide information about the severity of PH and how the heart and blood vessels are functioning.
- Other health conditions: Conditions affecting the heart, lungs, connective tissue, liver, or other organs can also affect outlook.
- Age and other individual factors: Age, sex, kidney function, and other characteristics may also influence outcomes.
- Treatment options and response: Whether a person’s disease’s underlying cause can be treated, as well as how they respond to treatment, can also affect their outlook.
What does functional class mean?
Functional class is a way of describing the severity of PH symptoms and how much PH affects the ability to carry out everyday activities. The WHO functional classification has four classes:
- Class I: PH with no significant limitations during ordinary physical activity.
- Class II: PH with mild limitations. While someone may be comfortable at rest, ordinary physical activity may cause symptoms such as shortness of breath, fatigue, chest discomfort, or near-fainting.
- Class III: PH with marked limitations. There may not be symptoms at rest, but less-than-ordinary physical activity such as chores around the house causes symptoms.
- Class IV: PH with symptoms accompanying any physical activity. There may also be symptoms while resting.
A higher functional class generally indicates more severe disease and is associated with a poorer prognosis. However, functional class is only one part of the overall assessment. Current guidelines recommend combining it with other measures when assessing risk, particularly in PAH.
How doctors assess risk
Doctors assess the severity of PH and the risk of disease progression by considering several factors, including symptoms, physical activity, heart function, test results, and the underlying cause of PH. The assessment helps guide treatment and monitor changes in condition over time.
For PAH, guidelines recommend using a risk assessment tool that combines several clinical measures to estimate the risk of disease progression and death. This helps doctors classify patients at diagnosis into three risk categories: low, intermediate, and high risk. At follow-up, a four-category model that includes low, intermediate-low, intermediate-high, and high risk is recommended.
According to the 2022 ESC/ERS guidelines, two registry studies of people with PAH reported one-year mortality rates of 0% to 3% in the low-risk group, 2% to 7% in the intermediate-low-risk group, 9% to 19% in the intermediate-high-risk group, and more than 20% in the high-risk group.
How PH survival rates are changing
Modern survival statistics should be interpreted differently from historical estimates. Older studies of PH were conducted before many of today’s diagnostic and treatment approaches became available, so historical survival figures may not reflect the outlook for someone diagnosed and treated today.
These statistics are useful for understanding trends, but they cannot predict exactly how long someone will live. A PH specialist will consider the specific disease type, risk status, treatment response, and other health factors when discussing outlook.
Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
